Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection
Luca Guarino, Giuseppe Rizzuto, Vincenzo Coppolelli, Alessia Scipione, Mirella Scattone, Luca Gargano, Pietro Scribani Rossi, Ester Del Duca, Annunziata Dattola, Giovanni Pellacani, Steven Nisticò, Camilla Chello · 2026
Read Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection by Luca Guarino, Giuseppe Rizzuto, Vincenzo Coppolelli, Alessia Scipione, Mirella Scattone, Luca Gargano, Pietro Scribani Rossi, Ester Del Duca, Annunziata Dattola, Giovanni Pellacani, Steven Nisticò, Camilla Chello (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13600177.txt.
Description
Twelve authors led by Luca Guarino sort the new targeted drugs for hives that shrug off antihistamine care. Such hives, chronic and un-called, are mast-cell driven and can rule a life. Till of late, one shot drug stood as the sole aimed pick, and a share of patients shrug it too. Two fresh drugs won marks in the past two years, and more queue in trials.
The review grades proof for each and sets a pick path by grade. One famed kin drug was dropped by its maker, a fact the tale keeps in view. Biosimilar forms of the old shot also join the shelf in the span. Guide books lag the shelf, so this sort fills a live gap.
Catalog record
| CREATOR | Luca Guarino, Giuseppe Rizzuto, Vincenzo Coppolelli, Alessia Scipione, Mirella Scattone, Luca Gargano, Pietro Scribani Rossi, Ester Del Duca, Annunziata Dattola, Giovanni Pellacani, Steven Nisticò, Camilla Chello |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |